Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 13 Dec 2018
At a glance
- Drugs Darifenacin (Primary) ; Fesoterodine (Primary) ; Imidafenacin (Primary) ; Mirabegron (Primary) ; Propiverine (Primary) ; Solifenacin (Primary) ; Tolterodine (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 13 Dec 2018 Last checked against ClinicalTrials.gov record.
- 03 Dec 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 31 Jul 2018 New trial record